<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="pku" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">pku</book-part-id>
      <title-group>
        <title>Phenylalanine Hydroxylase Deficiency</title>
        <alt-title alt-title-type="alt-title">Synonym: PAH Deficiency</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Regier</surname>
            <given-names>Debra S</given-names>
          </name>
          <degrees>MD, PhD, FAAP, FACMG</degrees>
          <aff>Children&#x02019;s National Medical Center<break/>Washington, DC</aff>
          <email>dregier@childrensnational.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Greene</surname>
            <given-names>Carol L</given-names>
          </name>
          <degrees>MD, FAAP, FACMG</degrees>
          <aff>University of Maryland School of Medicine<break/>Baltimore, Maryland</aff>
          <email>cgreene@peds.umaryland.edu</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>10</day>
          <month>1</month>
          <year>2000</year>
        </date>
        <date date-type="updated">
          <day>20</day>
          <month>10</month>
          <year>2016</year>
        </date>
        <date date-type="revised">
          <day>5</day>
          <month>1</month>
          <year>2017</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="gr_22q13_3" document-type="chapter">Phelan-McDermid Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="prs" document-type="chapter">Phosphoribosylpyrophosphate Synthetase Superactivity</related-object>
      <abstract id="pku.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Phenylalanine hydroxylase (PAH) deficiency results in intolerance to the dietary intake of the essential amino acid phenylalanine and produces a spectrum of disorders. The risk of adverse outcome varies based on the degree of PAH deficiency. Without effective therapy, most individuals with severe PAH deficiency, known as classic PKU, develop profound and irreversible intellectual disability. Affected individuals on an unrestricted diet who have phenylalanine levels above normal but below 1200 &#x003bc;mol/L (20 mg/dL) are at much lower risk for impaired cognitive development in the absence of treatment.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>PAH deficiency can be detected by newborn screening in virtually 100% of cases based on the presence of hyperphenylalaninemia using tandem mass spectrometry on a blood spot obtained from a heel prick. The diagnosis of PAH deficiency is established in a proband with:</p>
          <list list-type="bullet">
            <list-item>
              <p>A plasma phenylalanine concentration persistently above 120 &#x000b5;mol/L (2 mg/dL) and altered ratio of phenylalanine to tyrosine in the untreated state with normal BH4 cofactor metabolism;</p>
              <p>and/or</p>
            </list-item>
            <list-item>
              <p>The finding of biallelic pathogenic variants in <italic toggle="yes">PAH</italic> by molecular genetic testing.</p>
            </list-item>
          </list>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Classic PKU: a low-protein diet and use of a Phe-free medical formula as soon as possible after birth to achieve plasma Phe concentrations of 120-360 &#x000b5;mol/L (2-6 mg/dL). A proportion of individuals with PKU benefit from adjuvant therapy with sapropterin. Large neutral amino acid (LNAA) transporters may also decrease the plasma Phe concentration in affected adolescents and adults. Non-classic HPA: Individuals with plasma Phe concentrations above 600 &#x003bc;mol/L are treated in most centers. It is debatable whether those with plasma Phe concentrations consistently below 600 &#x000b5;mol/L (10 mg/dL) require dietary treatment. Neuropsychiatric testing may be considered to identify learning differences in affected individuals with referral to developmental services, as indicated.</p>
          <p>Prevention of primary manifestations: See <italic toggle="yes">Treatment of manifestations</italic>.</p>
          <p><italic toggle="yes">Surveillance:</italic> Regular monitoring of plasma Phe, Tyr, and plasma amino acid concentrations in individuals with classic PKU; regular assessment of growth and micronutrient needs; assessment of developmental progress and screening for mental illness at every visit.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Aspartame, an artificial sweetener that contains phenylalanine.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Newborn sibs of an individual with PAH deficiency who have not been tested prenatally should have blood concentration of Phe measured shortly after birth (in addition to newborn screening) to allow earliest possible diagnosis and treatment.</p>
          <p><italic toggle="yes">Pregnancy management:</italic> To minimize or prevent teratogenic effects of phenylalanine, women with PAH deficiency should follow a Phe-restricted diet for at least several months prior to conception in order to maintain plasma Phe concentrations between 120 and 360 &#x000b5;mol/L (2-6 mg/dL); after conception, continuous nutritional guidance and weekly or biweekly measurement of plasma Phe concentration to assure that target levels are met in addition to adequate energy intake with the proper proportion of protein, fat, and carbohydrates. Evaluation for fetal anomalies using high-resolution ultrasound and fetal echocardiogram.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>PAH deficiency is inherited in an autosomal recessive manner. At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier. Carrier testing for at-risk relatives and prenatal testing for pregnancies at increased risk are possible if the <italic toggle="yes">PAH</italic> pathogenic variants have been identified in an affected family member.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="pku.Diagnosis">
        <title>Diagnosis</title>
        <sec id="pku.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Phenylalanine hydroxylase (PAH) deficiency <bold>should be suspected</bold> in an individual with the following newborn screening results, clinical features (by age), neuroimaging, and supportive laboratory findings:</p>
          <p>
            <bold>Newborn screening results</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Positive newborn screen by tandem mass spectrometry (MS/MS) using dried blood spots collected after 24 hours of age. This method is used in most if not all states in the USA for <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://genes-r-us.uthscsa.edu/sites/genes-r-us/files/nbsdisorders.pdf">newborn screening</ext-link>.</p>
            </list-item>
            <list-item>
              <p>The ability of current tests to accurately measure Phe concentrations in infants before age 24 hours is a concern, since hyperphenylalaninemia (HPA) manifests itself as a time-dependent increase of Phe concentration in the blood. However, recognition of an altered ratio of phenylalanine and tyrosine may still identify the affected newborn.</p>
            </list-item>
          </list>
          <p><bold>Postnatal clinical findings in a newborn.</bold> No physical signs of hyperphenylalaninemia (HPA)</p>
          <p>
            <bold>Clinical findings in an untreated, older individual (infancy to adulthood)</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Epilepsy</p>
            </list-item>
            <list-item>
              <p>Any level of intellectual disability and behavior problems, including autistic features</p>
            </list-item>
            <list-item>
              <p>Parkinson-like features (particularly in an adult)</p>
            </list-item>
            <list-item>
              <p>Musty body odor</p>
            </list-item>
            <list-item>
              <p>Eczema</p>
            </list-item>
            <list-item>
              <p>Decreased skin and hair pigmentation</p>
            </list-item>
            <list-item>
              <p>Female with no prior normal offspring who has a history of recurrent pregnancy loss and/or offspring with malformations including any combination of small size, microcephaly/brain malformations, congenital heart defect, limb malformations, and/or tracheoesophageal fistula</p>
            </list-item>
          </list>
          <p><bold>Neuroimaging.</bold> Progressive white matter disease on brain MRI; observed in 90% of individuals with PAH deficiency even without evidence of neurologic deterioration</p>
          <list list-type="bullet">
            <list-item>
              <p>Advanced-age affected individuals off diet or with poor compliance and those who are untreated have the most severe MRI findings.</p>
            </list-item>
            <list-item>
              <p>It is proposed that in untreated affected individuals, Phe prevents myelination and in early-treated affected individuals, myelin is normally made but may be functionally impaired [<xref ref-type="bibr" rid="pku.REF.anderson.2010.s3">Anderson &#x00026; Leuzzi 2010</xref>].</p>
            </list-item>
          </list>
          <p>
            <bold>Supportive laboratory findings</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Plasma amino acid analysis.</bold> In the untreated state, an elevated plasma phenylalanine (Phe) concentration persistently higher than 120 &#x000b5;mol/L (2 mg/dL) with phenylalanine levels higher than tyrosine (Tyr) levels</p>
              <list list-type="bullet">
                <list-item>
                  <p>A normal Phe:Tyr ratio is typically &#x0003c;1; a ratio of &#x0003e;3 is considered useful in the diagnosis of PAH deficiency [<xref ref-type="bibr" rid="pku.REF.vockley.2014">Vockley et al 2014</xref>].</p>
                </list-item>
                <list-item>
                  <p>Most severely affected individuals with complete enzyme loss (also called &#x0201c;classic PKU&#x0201d;) have untreated levels of phenylalanine (Phe) of &#x0003e;1200 &#x000b5;mol/L. If diagnosed early and if treatment is begun in the first or second week of life, most severely affected individuals do not attain Phe levels this high.</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>
                <bold>BH4 (tetrahydrobiopterin) cofactor analysis and/or challenge</bold>
              </p>
              <list list-type="bullet">
                <list-item>
                  <p>Normal urine or dried blood spot pterins (neopterin and biopterins) studies using liquid chromatography</p>
                </list-item>
                <list-item>
                  <p>Normal dihydropterine reductase measurement in erythrocytes, typically from a dried blood spot</p>
                </list-item>
              </list>
            </list-item>
          </list>
        </sec>
        <sec id="pku.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of PAH deficiency <bold>is established</bold> in a proband with a plasma phenylalanine concentration persistently above 120 &#x000b5;mol/L (2 mg/dL) and altered ratio of phenylalanine to tyrosine in the untreated state, with normal BH<sub>4</sub> cofactor metabolism; and/or the finding of biallelic pathogenic variants in <italic toggle="yes">PAH</italic> by molecular genetic testing (see <xref ref-type="table" rid="pku.T.molecular_genetic_testing_used_in">Table 1</xref>).</p>
          <p>Note: (1) It is important that a low phenylalanine diet be initiated prior to receiving the results of the pterins or molecular genetic studies. (2) See <xref ref-type="sec" rid="pku.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref> for information on the clinical utility of a molecular diagnosis.</p>
          <p>Molecular testing approaches can include <bold>single-gene testing</bold> or use of a <bold>multi-gene panel</bold>.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Single-gene testing.</bold> Sequence analysis of <italic toggle="yes">PAH</italic> is performed first followed by gene-targeted deletion/duplication analysis if only one or no pathogenic variant is found.</p>
              <p>Targeted analysis for common pan ethnic pathogenic variants (see <xref ref-type="table" rid="pku.T.common_pathogenic_changes_in_pah_a">Table 2</xref>), as well as targeted analysis for founder pathogenic variants, may be performed. Note that founder variants in specific populations may be the same as those found in pan ethnic populations. For a full review of PAH pathogenic variant frequency, see the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.pahdb.mcgill.ca/">Phenylalanine Hydroxylase Knowledgebase</ext-link>.</p>
            </list-item>
            <list-item>
              <p><bold>A multi-gene panel</bold> that includes <italic toggle="yes">PAH</italic> and other genes of interest (see <xref ref-type="sec" rid="pku.Differential_Diagnosis">Differential Diagnosis</xref>) may also be considered. Note: The genes included in the panel and the diagnostic sensitivity of the testing used for each gene varies by laboratory and over time.</p>
            </list-item>
          </list>
          <table-wrap id="pku.T.molecular_genetic_testing_used_in" orientation="portrait" position="anchor">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Phenylalanine Hydroxylase Deficiency</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_pku.T.molecular_genetic_testing_used_in_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_pku.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_pku.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_pku.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">PAH</italic>
                  </td>
                  <td headers="hd_h_pku.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sequence analysis&#x000a0;<sup>3</sup></td>
                  <td headers="hd_h_pku.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">97%-99%</td>
                </tr>
                <tr>
                  <td headers="hd_h_pku.T.molecular_genetic_testing_used_in_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_pku.T.molecular_genetic_testing_used_in_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;1%-3%&#x000a0;<sup>5</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="pku.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="pku" object-id="pku.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="pku.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="pku.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="pku.TF.1.3">
                <label>3. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="pku.TF.1.4">
                <label>4. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="pku.TF.1.5">
                <label>5. </label>
                <p>This technique has been used to detect abnormal dosage in 20% of uncharacterized PKU alleles [<xref ref-type="bibr" rid="pku.REF.gable.2003.379">Gable et al 2003</xref>] and therefore duplications and deletions may account for up to 3% of pathogenic variants in the Czech population [<xref ref-type="bibr" rid="pku.REF.kozak.2006.300">Kozak et al 2006</xref>].</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Enzyme analysis</bold> is not usually indicated in the diagnosis of PAH deficiency because PAH is a hepatic enzyme and accurate, less invasive methods of diagnosis are available.</p>
          <p><bold>Test characteristics.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/ejhg/journal/v20/n2/full/ejhg2011172a.html">Clinical Utility Gene Card: Phenylketonuria</ext-link> [<xref ref-type="bibr" rid="pku.REF.zschocke.2012">Zschocke et al 2012</xref>] for information on test characteristics including sensitivity and specificity.</p>
        </sec>
      </sec>
      <sec id="pku.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="pku.Clinical_Description">
          <title>Clinical Description</title>
          <p>Phenylalanine hydroxylase (PAH) deficiency results in intolerance to the dietary intake of the essential amino acid phenylalanine and produces a spectrum of disorders [<xref ref-type="bibr" rid="pku.REF.vockley.2014">Vockley et al 2014</xref>]. Many terms have been used to describe the various clinical phenotypes that result from PAH deficiency (see <xref ref-type="sec" rid="pku.Nomenclature">Nomenclature</xref>). This <italic toggle="yes">GeneReview</italic> will follow the American College of Medical Genetics and Genomics (ACMGG) recommended convention.</p>
          <p>The risk of adverse outcome varies based on the degree of PAH deficiency. Without effective therapy, most individuals with severe PAH deficiency, known as classic PKU, develop profound and irreversible intellectual disability. Affected individuals on an unrestricted diet who have phenylalanine levels above normal but below 1200 &#x003bc;mol/L (20 mg/dL) are at much lower risk for impaired cognitive development in the absence of treatment. However, current understanding of these issues is not complete.</p>
          <sec id="pku.Untreated_Individuals_with_Persisten">
            <title>Untreated Individuals with Persistent Severe Hyperphenylalaninemia (i.e., Classic PKU)</title>
            <p>Affected individuals almost always show impaired brain development. Signs and symptoms include nearly invariable severe intellectual disability and behavior problems with a high frequency of seizures and variable microcephaly.</p>
            <p>The excretion of excessive phenylalanine and its metabolites can create a musty body odor and skin conditions such as eczema.</p>
            <p>The associated inhibition of tyrosinase and low tyrosine levels are responsible for decreased skin and hair pigmentation.</p>
            <p>Affected individuals also have decreased myelin formation, leading eventually to white matter changes on head MRI.</p>
            <p>Significantly elevated Phe levels decrease dopamine, norepinephrine, and serotonin production and can be reflected in electroencephalographic changes, which are reversible if the Phe level is reduced.</p>
          </sec>
          <sec id="pku.Individuals_with_Classic_PKU_Identif">
            <title>Individuals with Classic PKU Identified and Treated from Birth</title>
            <p><bold>Intelligence.</bold> The correlation between early elevated Phe levels and long-term decreases in IQ has been well studied. The benefit of normalized Phe levels on IQ throughout life has also been shown in studies of affected adults.</p>
            <list list-type="bullet">
              <list-item>
                <p>Those who decrease their adherence to a Phe-restricted diet in adulthood have a small drop in IQ, further supporting the current advice of &#x0201c;diet for life&#x0201d; (see <xref ref-type="sec" rid="pku.Management">Management</xref>) [<xref ref-type="bibr" rid="pku.REF.brumm.2010.s18">Brumm &#x00026; Grant 2010</xref>, <xref ref-type="bibr" rid="pku.REF.vockley.2014">Vockley et al 2014</xref>, <xref ref-type="bibr" rid="pku.REF.jahja.2016.355">Jahja et al 2016</xref>].</p>
              </list-item>
              <list-item>
                <p>However, even with strict adherence to a low phenylalanine (Phe) diet, adults may still have some underlying sequelae and suboptimal cognitive outcomes affecting language skills, memory, learning skills, and executive function [<xref ref-type="bibr" rid="pku.REF.moyle.2007.91">Moyle et al 2007</xref>, <xref ref-type="bibr" rid="pku.REF.waisbren.2007.63">Waisbren et al 2007</xref>, <xref ref-type="bibr" rid="pku.REF.antshel.2010.s52">Antshel 2010</xref>, <xref ref-type="bibr" rid="pku.REF.burton.2013.8">Burton et al 2013</xref>].</p>
              </list-item>
            </list>
            <p><bold>Neuropsychological issues.</bold> In treated individuals, certain psychological problems are increased &#x02013; as compared to unaffected sibs or children with other chronic diseases [<xref ref-type="bibr" rid="pku.REF.brumm.2010.s59">Brumm et al 2010</xref>, <xref ref-type="bibr" rid="pku.REF.bilder.2013.155">Bilder et al 2013</xref>].</p>
            <list list-type="bullet">
              <list-item>
                <p>Adults who have increased Phe levels typically due to relaxed Phe-restricted diet tend to have a reduced attention span, slow information-processing abilities, and slow motor reaction time [<xref ref-type="bibr" rid="pku.REF.channon.2007.213">Channon et al 2007</xref>, <xref ref-type="bibr" rid="pku.REF.moyle.2007.91">Moyle et al 2007</xref>]. These findings appear to be related to both current and historic phenylalanine levels [<xref ref-type="bibr" rid="pku.REF.huijbregts.2002.419">Huijbregts et al 2002</xref>, <xref ref-type="bibr" rid="pku.REF.fonnesbeck.2013.757">Fonnesbeck et al 2013</xref>].</p>
              </list-item>
              <list-item>
                <p>There is also a higher incidence of anxiety, depression, phobias, and panic attacks in early-treated individuals who discontinued therapy in the second decade of life [<xref ref-type="bibr" rid="pku.REF.koch.2002.333">Koch et al 2002</xref>].</p>
              </list-item>
            </list>
            <p><bold>Neurologic.</bold> Early-treated adults who discontinue diet are also at risk for minor neurologic abnormalities such as tremor and brisk reflexes [<xref ref-type="bibr" rid="pku.REF.pietz.1998.824">Pietz et al 1998</xref>] and, in some cases, more severe neurologic dysfunction, including paralysis. Return to diet often resolves these neurologic symptoms [<xref ref-type="bibr" rid="pku.REF.camp.2014.87">Camp et al 2014</xref>].</p>
          </sec>
          <sec id="pku.PAH_with_Milder_Biochemical_and_Clin">
            <title>PAH with Milder Biochemical and Clinical Phenotypes</title>
            <p>Individuals with PAH deficiency and <bold>plasma Phe between 600 and 1200 &#x003bc;mol/L (10-20 mg/dL)</bold> on an unrestricted diet have not been extensively studied. However, it is well documented that individuals with classic PKU who have levels in this range have both acute and chronic neuropsychological problems. Therefore, treatment with a Phe-restricted diet is recommended for individuals with Phe levels in this range.</p>
            <p>Individuals with PAH deficiency who have plasma <bold>Phe concentrations consistently below 600 &#x000b5;mol/L (10 mg/dL)</bold> on an unrestricted diet are considered by many experts not to be at higher risk of developing intellectual, neurologic, and neuropsychological impairment than are individuals without PAH deficiency. However, since evidence suggests that individuals with classic PKU have demonstrable neurophysiologic changes when Phe levels are between 360 and 600 &#x003bc;mol/L (6 to 10 mg/dL), other experts recommend Phe restriction for any individual who has Phe levels &#x0003e;360 &#x003bc;mol/L (6 mg/dL) on an unrestricted diet. A very small number of programs begin therapy for individuals with Phe levels &#x0003e;240 &#x003bc;mol/L (4 mg/dL). As Phe is an essential amino acid, having inadequate phenylalanine leads to growth restriction, microcephaly and developmental problems. The safety of dietary restriction of Phe for individuals with the milder PAH deficiency has not been systematically studied. Practices vary around the world [<xref ref-type="bibr" rid="pku.REF.blau.2010.109">Blau et al 2010</xref>].</p>
            <p>In a few case reports untreated individuals with mild PAH deficiency who had normal intelligence were diagnosed in adulthood as a result of sudden and severe psychiatric deterioration [<xref ref-type="bibr" rid="pku.REF.weglage.2000.83">Weglage et al 2000</xref>, <xref ref-type="bibr" rid="pku.REF.camp.2014.87">Camp et al 2014</xref>].</p>
          </sec>
          <sec id="pku.Other">
            <title>Other</title>
            <p><bold>Osteopenia.</bold> While numerous studies indicate that individuals with PAH deficiency have a high incidence of osteopenia (as measured by DEXA) [<xref ref-type="bibr" rid="pku.REF.zeman.1999.1348">Zeman et al 1999</xref>, <xref ref-type="bibr" rid="pku.REF.p_rezdue_as.2002.899">P&#x000e9;rez-Due&#x000f1;as et al 2002</xref>, <xref ref-type="bibr" rid="pku.REF.modanmoses.2007.202">Modan-Moses et al 2007</xref>], a recent meta-analysis showed that the combined data does not support a high risk based on World Health Organization and International Society for Clinical Densitometry measurement guidelines [<xref ref-type="bibr" rid="pku.REF.demirdas.2015.17">Demirdas et al 2015</xref>]. Studies to explore the mechanism of low bone density and clinical significance are underway. Until additional studies are performed, it is important to continue to closely monitor the bone health of individuals with PAH deficiency. A recent study of individuals with PAH deficiency by <xref ref-type="bibr" rid="pku.REF.coakley.2016.363">Coakley et al [2016]</xref> identified risk factors for lower Z-scores, with the highest significance for dietary prescription compliance in an adult population.</p>
            <p><bold>Vitamin B<sub>12</sub> deficiency</bold> can occur when individuals with PKU relax their diet in adolescence [<xref ref-type="bibr" rid="pku.REF.robinson.2000.545">Robinson et al 2000</xref>]. This vitamin is found in natural animal protein; when affected individuals decrease their amino acid supplementation, they often still choose low-protein foods and are therefore at risk for vitamin B<sub>12</sub> deficiency.</p>
          </sec>
          <sec id="pku.Children_Born_to_Women_with_PAH_Defi">
            <title>Children Born to Women with PAH Deficiency</title>
            <p>The abnormalities that result from exposure of a fetus to high maternal plasma Phe concentration are the result of maternal PAH deficiency. Risks include the following [<xref ref-type="bibr" rid="pku.REF.vockley.2014">Vockley et al 2014</xref>]:</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Intellectual disability</bold> (&#x0003e;90%).The threshold for this finding is a maternal Phe concentration consistently above 360 &#x000b5;mol/L during pregnancy with an inverse relationship between cognitive function and maternal Phe level above 360 &#x000b5;mol/L.</p>
              </list-item>
              <list-item>
                <p>
                  <bold>Poor behavioral outcomes</bold>
                </p>
              </list-item>
              <list-item>
                <p><bold>Microcephaly.</bold> The risk is 5%-18% in pregnancies in which the maternal Phe level is optimized prior to ten weeks&#x02019; gestation and increases to 67% if appropriate Phe levels are not achieved by 30 weeks&#x02019; gestation.</p>
              </list-item>
              <list-item>
                <p><bold>Congenital heart defect and other malformations.</bold> Due to the early formation of the heart, consistently elevated maternal Phe concentrations (&#x0003e;600 &#x000b5;mol/L) during early gestation leads to an approximately 8%-12% risk of cardiac malformations. Minor dysmorphic features and other birth defects have also been reported in infants born to women with maternal PKU, including tracheoesophageal fistula.</p>
              </list-item>
              <list-item>
                <p><bold>Intrauterine growth restriction (IUGR).</bold> Frequency is not different from that in the general population if maternal Phe levels are controlled by week 10 of gestation; the risk of IUGR increases if the Phe concentration is optimized later in pregnancy.</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="pku.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>More than 900 pathogenic variants have been described in <italic toggle="yes">PAH</italic> (see www.BIOPKU.org and the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.pahdb.mcgill.ca/">Phenylalanine Hydroxylase Knowledgebase</ext-link>). While both genetic (particular pathogenic variant) and environmental (dietary consumption) components contribute to an affected individual&#x02019;s total plasma Phe level, knowledge of the specific genetic cause can offer insight helpful for long-term management [<xref ref-type="bibr" rid="pku.REF.zschocke.2000.s154">Zschocke &#x00026; Hoffmann 2000</xref>, <xref ref-type="bibr" rid="pku.REF.national_institutes_of_health_consensus_development_panel.2001.972">National Institutes of Health Consensus Development Panel 2001</xref>, <xref ref-type="bibr" rid="pku.REF.g_ttler.2006">G&#x000fc;ttler &#x00026; Guldberg 2006</xref>, <xref ref-type="bibr" rid="pku.REF.santos.2010.1">Santos et al 2010</xref>].</p>
          <p>In compound heterozygotes with functional hemizygosity (null/missense paired alleles), the less severe of the two <italic toggle="yes">PAH</italic> pathogenic variants determines disease severity. However, when two pathogenic variants associated with similar severity are present, the phenotype may be milder than predicted by either allele [<xref ref-type="bibr" rid="pku.REF.kayaalp.1997.1309">Kayaalp et al 1997</xref>, <xref ref-type="bibr" rid="pku.REF.guldberg.1998.71">Guldberg et al 1998</xref>, <xref ref-type="bibr" rid="pku.REF.waters.1998.4">Waters et al 1998</xref>].</p>
          <p>In general, affected individuals with milder <italic toggle="yes">PAH</italic> pathogenic variants have a better response to sapropterin (B6BH4, Kuvan&#x02122;) (see <xref ref-type="sec" rid="pku.Management">Management</xref>). The current guidelines recommend that all affected individuals (except those with two pathogenic null variants in <italic toggle="yes">trans</italic>) be offered a trial with sapropterin (B6BH4, Kuvan&#x02122;) because of the difficulty of predicting the phenotype from the genotype [<xref ref-type="bibr" rid="pku.REF.vockley.2014">Vockley et al 2014</xref>]. See <xref ref-type="sec" rid="pku.Molecular_Genetics">Molecular Genetics</xref> for more information on common pathogenic variants in <italic toggle="yes">PAH</italic> and their reported responsiveness to sapropterin therapy.</p>
          <table-wrap id="pku.T.common_pathogenic_changes_in_pah_a" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Common Pathogenic Changes in <italic toggle="yes">PAH</italic> and Their Responsiveness to Sapropterin</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">cDNA</th>
                  <th id="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein</th>
                  <th id="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Cases in PAHdb</th>
                  <th id="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Responsive to Sapropterin</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1222C&#x0003e;T</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg408Trp</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">6.7%</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;10%</td>
                </tr>
                <tr>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1066-11G&#x0003e;A<break/>(IVS10-11G&#x0003e;A)</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">5.3%</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;10%</td>
                </tr>
                <tr>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.194T&#x0003e;C</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ile65Thr</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">4.1%</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">89%</td>
                </tr>
                <tr>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.782G&#x0003e;A</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg261Gln</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">3.6%</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">78%</td>
                </tr>
                <tr>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.842C&#x0003e;T</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Pro281Leu</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">2.9%</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">None [<xref ref-type="bibr" rid="pku.REF.leuders.2014.101">Leuders et al 2014</xref>, <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.biopku.org/">biopku.org</ext-link>]</td>
                </tr>
                <tr>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1315+1G&#x0003e;A<break/>(IVS12+1G&#x0003e;A)</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">2.8%</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">12.5% [<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.biopku.org/">biopku.org</ext-link>]<break/>None [<xref ref-type="bibr" rid="pku.REF.leuders.2014.101">Leuders et al 2014</xref>]</td>
                </tr>
                <tr>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.473G&#x0003e;A</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Arg158Gln</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">2.7%</td>
                  <td headers="hd_h_pku.T.common_pathogenic_changes_in_pah_a_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x0003c;10%</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Data obtained from: PAHdb accessed 5/8/2016 (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.biopku.org/">www.biopku.org</ext-link>); and <xref ref-type="bibr" rid="pku.REF.leuders.2014.101">Leuders et al [2014]</xref>. All changes with &#x0003e;2.5% frequency in the PAHdb database were included. In database searches, homozygosity was assumed for calculations; however, this is a rare finding in consanguineous individuals. It is recommended that all affected individuals be tested for personal responsiveness. Genetic changes shown affect &#x0003e;2.5% of the database population. See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.biopku.org/">www.biopku.org</ext-link> for the most up-to-date information and additional references.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>However, genotype-phenotype correlation becomes more complex when clinical outcomes are also taken into account. While <xref ref-type="bibr" rid="pku.REF.disilvestre.1991.1014">DiSilvestre et al [1991]</xref> found that genotype does predict biochemical phenotype (i.e., by Phe loading tests), it does not always predict clinical phenotype (i.e., occurrence of intellectual disability). Some untreated individuals with PAH deficiency and biallelic <italic toggle="yes">PAH</italic> pathogenic variants that usually result in classic PKU have elevated plasma Phe concentration but normal intelligence. In other instances, sibs with the same genotype have different clinical and metabolic phenotypes. While mechanisms that cause dissimilarities in pathogenesis at the level of the brain in spite of comparable plasma Phe concentrations are not fully understood [<xref ref-type="bibr" rid="pku.REF.scriver.1999.267">Scriver &#x00026; Waters 1999</xref>], there is evidence that variation in transport of Phe across the blood-brain barrier is at least one relevant factor [<xref ref-type="bibr" rid="pku.REF.weglage.2002.431">Weglage et al 2002</xref>].</p>
        </sec>
        <sec id="pku.Nomenclature">
          <title>Nomenclature</title>
          <p>The 2014 American College of Medical Genetics and Genomics guidelines on the diagnosis and management of PAH (PKU) recommends the term &#x0201c;phenylalanine hydroxylase (PAH) deficiency&#x0201d; to describe all affected individuals, in order to best recognize that there is a spectrum of PAH deficiency. The guideline recognizes that the most severe expression of that spectrum will continue to be termed &#x0201c;classic PKU.&#x0201d; They also recognized that other classification schema in historical use suggested the use of the term hyperphenylalaninemia (hyperPhe or HPA) for those who have Phe levels on an unrestricted diet that are above normal but below 1200 &#x003bc;mol/L (20 mg/dL) [<xref ref-type="bibr" rid="pku.REF.vockley.2014">Vockley et al 2014</xref>].</p>
          <sec id="pku.Alternative_Nomenclature_Systems">
            <title>Alternative Nomenclature Systems</title>
            <p>In the early literature there was no universal system of nomenclature; thus, it was necessary to understand how terms were used in a given report to interpret the significance of the observations regarding PAH activity. In response to this difficulty, various systems of nomenclature have been proposed.</p>
            <p><xref ref-type="bibr" rid="pku.REF.camp.2014.87">Camp et al [2014]</xref> provide, as part of an NIH systematic review of PKU, a recommendation for terminology of PAH deficiency (from most to least severe) of &#x0201c;classic PKU,&#x0201d; &#x0201c;moderate PKU,&#x0201d; &#x0201c;mild PKU,&#x0201d; &#x0201c;mild HPA-gray zone,&#x0201d; and &#x0201c;mild HPA-NT (no treatment),&#x0201d; and a table mapping the various terms to the level of blood Phe when untreated, to the dietary tolerance of Phe, and to the observed or expected level of PAH activity. This table of nomenclature will be of particular value to those wishing to understand the relationship between the various historical systems of nomenclature. See Table 2 in <xref ref-type="bibr" rid="pku.REF.camp.2014.87">Camp et al [2014]</xref>.</p>
            <p>An early classification scheme proposed by <xref ref-type="bibr" rid="pku.REF.kayaalp.1997.1309">Kayaalp et al [1997]</xref> was intended to simplify the nomenclature. In this system:</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Phenylketonuria (PKU)</bold> is the most severe of the three types and in an untreated state is associated with plasma Phe concentrations &#x0003e;1000 &#x000b5;mol/L and a dietary Phe tolerance of &#x0003c;500 mg/day. PKU is associated with a high risk of severely impaired cognitive development.</p>
              </list-item>
              <list-item>
                <p><bold>Non-PKU hyperphenylalaninemia (non-PKU HPA)</bold> is associated with plasma Phe concentrations consistently above normal (i.e., &#x0003e;120 &#x000b5;mol/L) but lower than 1000 &#x000b5;mol/L when an individual is on a normal diet. Individuals with non-PKU HPA are at a much lower risk for impaired cognitive development in the absence of treatment.</p>
              </list-item>
              <list-item>
                <p><bold>Variant PKU</bold> includes those individuals who do not fit the description for either PKU or non-PKU HPA.</p>
              </list-item>
            </list>
            <p>A classification scheme proposed by <xref ref-type="bibr" rid="pku.REF.guldberg.1998.71">Guldberg et al [1998]</xref> subdivides PAH deficiency into the following four categories:</p>
            <list list-type="bullet">
              <list-item>
                <p><bold>Classic PKU</bold> is caused by a complete or near-complete deficiency of PAH activity. Affected individuals tolerate less than 250-350 mg of dietary phenylalanine per day to keep plasma concentration of Phe at a safe level of &#x02264;300 &#x000b5;mol/L (5 mg/dL). Without dietary treatment most individuals develop profound, irreversible intellectual disability.</p>
              </list-item>
              <list-item>
                <p><bold>Moderate PKU.</bold> Affected individuals tolerate 350-400 mg of dietary phenylalanine per day.</p>
              </list-item>
              <list-item>
                <p><bold>Mild PKU.</bold> Affected individuals tolerate 400-600 mg of dietary phenylalanine per day.</p>
              </list-item>
              <list-item>
                <p><bold>Mild hyperphenylalaninemia (MHP).</bold> Affected infants have plasma Phe concentrations &#x0003c;600 &#x000b5;mol/L (10 mg/dL) on a normal diet.</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="pku.Prevalence">
          <title>Prevalence</title>
          <p>PAH deficiency varies in frequency from more than 1:5,000 (Turkey, Ireland) to approximately 1:10,000 in those of northern European and East Asian origin (lower in Finland and Japan). Classic PKU was once the most common identifiable etiology of severe intellectual disability in institutions for the developmentally disabled in Europe and North America, but since the adoption of universal newborn screening in many countries, symptomatic classic PKU is less frequently seen. The predicted incidence of severe intellectual disability resulting from PKU in screened populations &#x02013; fewer than one in a million live births &#x02013; reflects those children not detected by newborn screening. See <xref ref-type="table" rid="pku.T.prevalence_of_pah_deficiency_by_po">Table 3</xref>.</p>
          <table-wrap id="pku.T.prevalence_of_pah_deficiency_by_po" orientation="portrait" position="anchor">
            <label>Table 3. </label>
            <caption>
              <p>Prevalence of PAH Deficiency by Population</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Population</th>
                  <th id="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">PAH Deficiency in Live Births</th>
                  <th id="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Carrier Rate</th>
                  <th id="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Turks</td>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:2,600</td>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">1/26</td>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="pku.REF.ozalp.2001.97">Ozalp et al [2001]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Irish</td>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:4,500</td>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">1/33</td>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="pku.REF.dilella.1986.743">DiLella et al [1986]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Northern European origin, East Asian</td>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:10,000</td>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">1/50</td>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="pku.REF.scriver.2001">Scriver &#x00026; Kaufman [2001]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Japanese</td>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:143,000</td>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">1/200</td>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="pku.REF.aoki.1988.429">Aoki &#x00026; Wada [1988]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Finnish, Ashkenazi Jewish</td>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1:200,000</td>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">1/225</td>
                  <td headers="hd_h_pku.T.prevalence_of_pah_deficiency_by_po_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="pku.REF.scriver.2001">Scriver &#x00026; Kaufman [2001]</xref>
                  </td>
                </tr>
              </tbody>
            </table>
          </table-wrap>
          <p>Click <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="pku-historical_perspective.pdf" content-type="local-data">here</inline-supplementary-material> (pdf) for a historical perspective.</p>
        </sec>
      </sec>
      <sec id="pku.Genetically_Related_Allelic_Disorder">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>No phenotypes other than those discussed in this <italic toggle="yes">GeneReview</italic> are known to be associated with pathogenic variants of <italic toggle="yes">PAH</italic>.</p>
      </sec>
      <sec id="pku.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Tetrahydrobiopterin (BH<sub>4</sub>) deficiency.</bold> Hyperphenylalaninemia may also result from the impaired synthesis or recycling of tetrahydrobiopterin (BH<sub>4</sub>), the cofactor in the phenylalanine, tyrosine, and tryptophan hydroxylation reactions. All of the HPAs caused by BH<sub>4</sub> deficiency are inherited in an autosomal recessive manner. They account for approximately 2% of individuals with elevated Phe levels in most populations. However, for individuals with elevated Phe from populations in which PAH is less common (e.g., Japan), the risk to the affected individual of having a disorder of pterin metabolism is much higher. BH<sub>4</sub> is also involved in catecholamine, serotonin, and nitric oxide biosynthesis (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.biopku.org/home/home.asp">www.biopku.org</ext-link>).</p>
        <list list-type="bullet">
          <list-item>
            <p>Defects in BH<sub>4</sub> synthesis result from guanosine triphosphate cyclohydrolase (GTPCH) deficiency (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/233910">OMIM</ext-link>) caused by biallelic pathogenic variants in <italic toggle="yes">GCH1</italic> or from 6-pyruvoyl tetrahydrobiopterin synthase (PTPS) deficiency (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/261640">OMIM</ext-link>) caused by biallelic pathogenic variants in <italic toggle="yes">PTS</italic>.</p>
          </list-item>
          <list-item>
            <p>Impaired recycling of BH<sub>4</sub> is caused by dihydropteridine reductase (DHPR) deficiency (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/261630">OMIM</ext-link>) caused by biallelic pathogenic variants in <italic toggle="yes">QDPR</italic> or by pterin-4 acarbinolamine dehydratase (PCBD) deficiency (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/264070">OMIM</ext-link>) caused by biallelic pathogenic variants in <italic toggle="yes">PCBD1</italic>.</p>
          </list-item>
        </list>
        <p><xref ref-type="bibr" rid="pku.REF.vockley.2014">Vockley et al [2014]</xref> emphasize that all neonates with persistent hyperphenylalaninemia must be screened for the BH<sub>4</sub> deficiencies. The following tests are best performed in specialized centers. Prenatal diagnosis is possible for all forms of BH<sub>4</sub> deficiencies. The following screening tests are essential:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pterins are measured in urine or blood.</p>
          </list-item>
          <list-item>
            <p>Erythrocyte dihydropterine reductase should be measured on whole blood spotted on filter paper. A quantitative assay for urinary neopterin and biopterin can confirm results obtained from the filter paper samples. Reference values are available for different age groups.</p>
          </list-item>
          <list-item>
            <p>Abnormal pterin levels and ratios should prompt enzyme testing for possible deficiencies of: GTP cyclohydrolase, 6-pyruvoyl-tetrahydropterin synthase, dihydropteridine reductase, or pterin carbinolamine-4&#x003b1;-dehydratase.</p>
          </list-item>
        </list>
        <p>The typical (severe) forms of GTPCH, PTPS, and DHPR deficiency have the following variable, but common, findings: intellectual disability, convulsions, disturbance of tone and posture, drowsiness, irritability, abnormal movements, recurrent hyperthermia without infections, hypersalivation, and swallowing difficulties. Microcephaly is common in PTPS and DHPR deficiencies. Plasma phenylalanine concentrations can vary from slightly above normal (&#x0003e;120 &#x000b5;mol/L) to as high as 2500 &#x000b5;mol/L. Mild forms of BH<sub>4</sub> deficiency have no clinical signs.</p>
        <p>PCD deficiency, sometimes referred to as 'primapterinuria' is associated with benign transient hyperphenylalaninemia and patients are at risk for MODY-type diabetes at puberty.</p>
        <p>In principle, BH<sub>4</sub> deficiencies are treatable. Treatment requires the normalization of BH<sub>4</sub> availability and of blood Phe concentration and restoration of the BH<sub>4</sub>-dependent hydroxylation of tyrosine and tryptophan. This is achieved by BH<sub>4</sub> supplementation along with dietary modification, neurotransmitter precursor replacement therapy, and supplements of folinic acid in DHPR deficiency. The treatment should be initiated early and probably continued for life [<xref ref-type="bibr" rid="pku.REF.blau.2001">Blau et al 2001</xref>, <xref ref-type="bibr" rid="pku.REF.ponzone.2006">Ponzone et al 2006</xref>].</p>
        <p>More information on the BH<sub>4</sub> deficiencies can be found at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.biopku.org/">www.biopku.org</ext-link>.</p>
      </sec>
      <sec id="pku.Management">
        <title>Management</title>
        <sec id="pku.Evaluations_Following_Initial_Diagno">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with phenylalanine hydroxylase (PAH) deficiency, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Medical biochemical genetics consultation, if not already done, and evaluation by a metabolic dietician able to begin a low Phe, age-appropriate diet</p>
            </list-item>
            <list-item>
              <p>Blood phenylalanine concentration and estimation of phenylalanine tolerance [<xref ref-type="bibr" rid="pku.REF.kayaalp.1997.1309">Kayaalp et al 1997</xref>, <xref ref-type="bibr" rid="pku.REF.guldberg.1998.71">Guldberg et al 1998</xref>]. Because the PAH genotype may not always predict phenotype (see <xref ref-type="sec" rid="pku.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>), the individual's diet should be tailored to the estimated phenylalanine tolerance irrespective of genotype.</p>
            </list-item>
            <list-item>
              <p>For individuals diagnosed outside the newborn period, formal developmental, behavioral, neuropsychological, and mental health evaluation</p>
            </list-item>
          </list>
        </sec>
        <sec id="pku.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Treatment for affected individuals of all ages can be difficult and is enhanced with the teaching and support of an experienced healthcare team consisting of physicians, nutritionists, genetic counselors, social workers, nurses, and psychologists. See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.acmg.net/docs/Phenylalanine_Hydrosylase_Deficiency_Practice_Guideline_AOP_Jan_2013.pdf">ACMG Management Guidelines for PKU</ext-link>.</p>
          <sec id="pku.Treatment_of_Classic_PKU">
            <title>Treatment of Classic PKU</title>
            <p><bold>Restriction of dietary phenylalanine.</bold> The generally accepted goal of treatment for individuals with PAH deficiency is normalization of the concentrations of Phe (phenylalanine) and Tyr (tyrosine) in the blood and thus prevention of the cognitive deficits that are attributable to this disorder [<xref ref-type="bibr" rid="pku.REF.burgard.1999.46">Burgard et al 1999</xref>].</p>
            <p>Genetic Metabolic Dieticians International (GMDI) has <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://southeastgenetics.org/ngp/guidelines.php/90/PKU%20Nutrition%20Guidelines/Version%201.12">PKU Nutrition Management Guidelines</ext-link> that are continually updated.</p>
            <p>Any provider managing the diet of an individual with PAH deficiency should use these resources and work closely with a dietician knowledgeable in the care and management of a person with this diagnosis.</p>
            <p><xref ref-type="bibr" rid="pku.REF.singh.2014.121">Singh et al [2014]</xref> provide the following dietary recommendations:</p>
            <list list-type="bullet">
              <list-item>
                <p>Maintain blood Phe between 120 and 360 &#x003bc;mol/L throughout the life span.</p>
              </list-item>
              <list-item>
                <p>Monitor blood Phe most frequently during times of increased anabolism: infancy, childhood, and pregnancy. The NIH recommends measurement of blood phenylalanine levels on a weekly basis for the first year of life, on a biweekly basis until age 13 years, and on a monthly basis thereafter [<xref ref-type="bibr" rid="pku.REF.camp.2014.87">Camp et al 2014</xref>]. Care must be taken to avoid long periods of low blood Phe concentration, which is also harmful to brain development and function.</p>
              </list-item>
              <list-item>
                <p>Monitor blood Phe consistently, preferably two to three hours after eating.</p>
              </list-item>
              <list-item>
                <p>Evaluate individual nutritional needs, ability to adhere to recommendations, and access to treatment options when choosing appropriate interventions (medical food, modified low-protein food, large neutral amino acids [LNAAs], and sapropterin) to achieve blood PHE in the target range.</p>
              </list-item>
              <list-item>
                <p>Include breast milk [<xref ref-type="bibr" rid="pku.REF.vockley.2014">Vockley et al 2014</xref>] and/or infant formula as sources of Phe in the diet of an infant with PAH deficiency.</p>
              </list-item>
              <list-item>
                <p>Recommend that medical food be consumed throughout the day for optimal metabolic control.</p>
              </list-item>
              <list-item>
                <p>Track Phe intake by any of several methods, including counting milligrams or exchanges of PHE or grams of protein.</p>
              </list-item>
              <list-item>
                <p>Maintain blood Tyr in the normal range.</p>
              </list-item>
              <list-item>
                <p>Maintain other nutrients and micronutrients at RDA levels, including calcium, vitamin D, iron, and B vitamins. Due to the protein-restricted dietary components, micronutrients found in animal products must be carefully monitored and supplemented, as needed.</p>
              </list-item>
              <list-item>
                <p>Provide counseling and education specific to the needs of the individual with PAH deficiency (and/or his/her caregivers) to help maintain appropriate blood Phe throughout the life span.</p>
              </list-item>
            </list>
            <p><bold>Sapropterin (Kuvan<sup>&#x000ae;</sup>).</bold> BH<sub>4</sub> responsiveness, as determined by a 30% decrease in Phe plasma levels on plasma amino acid analysis, is determined based on response to a pharmacologic dose of BH<sub>4</sub> (10-20 mg/kg per day):</p>
            <list list-type="bullet">
              <list-item>
                <p>All affected individuals except those with two <italic toggle="yes">trans</italic> pathogenic null variants should ideally undergo a trial with sapropterin supplementation. The trial needs to be conducted when Phe levels have been stable and dietary intake can remain unchanged, so that any change in Phe level is the result of the medication; for some affected individuals it is a challenge to conduct a trial of therapy. The most common dose given is 20 mg/kg per day. Lower trial doses may lead to false negative responsiveness results [<xref ref-type="bibr" rid="pku.REF.vockley.2014">Vockley et al 2014</xref>].</p>
              </list-item>
              <list-item>
                <p>Affected individuals who are responsive should continue this medication with compensatory dietary Phe liberalization, as needed, to maintain a safe Phe level between 120 and 360 &#x003bc;mol/L.</p>
              </list-item>
              <list-item>
                <p>The majority of individuals with mild or moderate PKU may be responsive to sapropterin while up to 10% of individuals with classic PKU show a response [<xref ref-type="bibr" rid="pku.REF.bernegger.2002.304">Bernegger &#x00026; Blau 2002</xref>, <xref ref-type="bibr" rid="pku.REF.p_rezdue_as.2004.1083">P&#x000e9;rez-Due&#x000f1;as et al 2004</xref>, <xref ref-type="bibr" rid="pku.REF.zurfl_h.2006.725">Zurfl&#x000fc;h et al 2006</xref>]. Reviewed in <xref ref-type="bibr" rid="pku.REF.ho.2014.49">Ho &#x00026; Christodoulou [2014]</xref>.</p>
              </list-item>
            </list>
            <p>Click <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="pku-mech_action.pdf" content-type="local-data">here</inline-supplementary-material> (pdf) for more information on the proposed mechanism of action of sapropterin.</p>
            <p><bold>Large neutral amino acids (LNAA) transporters.</bold> LNAA may decrease the plasma Phe concentration in affected adolescents and adults; however, it should not be used in women of child-bearing age (see <xref ref-type="sec" rid="pku.Pregnancy_Management">Pregnancy Management</xref>).</p>
            <p>Click <inline-supplementary-material xmlns:xlink="http://www.w3.org/1999/xlink" xlink:title="media" xlink:href="pku-mech_action.pdf" content-type="local-data">here</inline-supplementary-material> (pdf) for more information on the proposed mechanism of action of LNAA</p>
          </sec>
          <sec id="pku.Treatment_for_NonClassic_Hyperphenyl">
            <title>Treatment for Non-Classic Hyperphenylalaninemia</title>
            <p>While debate continues, many experts believe that dietary treatment is unnecessary for many of the individuals in this class.</p>
            <list list-type="bullet">
              <list-item>
                <p>Individuals with <bold>Phe levels &#x0003e;600 &#x003bc;mol/L (10 mg/dL)</bold> are treated by most centers, in recognition of the finding of head MRI changes and neuropsychological findings in at least some affected individuals.</p>
              </list-item>
              <list-item>
                <p>Treatment in individuals with <bold>Phe levels consistently &#x0003c;600 &#x003bc;mol/L but &#x0003e;360 &#x003bc;mol/L</bold> remains controversial [<xref ref-type="bibr" rid="pku.REF.weglage.2001.532">Weglage et al 2001</xref>, <xref ref-type="bibr" rid="pku.REF.hanley.2011.23">Hanley 2011</xref>, <xref ref-type="bibr" rid="pku.REF.van_spronsen.2011.651">van Spronsen 2011</xref>].</p>
                <list list-type="bullet">
                  <list-item>
                    <p>Thirty-one individuals with PAH deficiency who were never treated and whose plasma Phe concentrations did not exceed 600 &#x000b5;mol/L had normal cognitive neuropsychological development.</p>
                  </list-item>
                  <list-item>
                    <p>The American College of Medical Genetics and Genomics guidelines on the diagnosis and management of PAH (PKU) state: &#x0201c;&#x02026;treatment of infants with sustained blood Phe levels &#x0003e;360 &#x000b5;mol/L is recommended following appropriate review of the controversy with patients.&#x0201d;</p>
                  </list-item>
                </list>
              </list-item>
              <list-item>
                <p>If the <bold>Phe levels remain between 120 and 360 &#x000b5;mol/L</bold>, treatment is not recommended; however, children should be followed for plasma Phe levels closely during the first two years of life, then on an annual or biennial basis [<xref ref-type="bibr" rid="pku.REF.vockley.2014">Vockley et al 2014</xref>].</p>
              </list-item>
              <list-item>
                <p>Care should be taken so that women of childbearing age in this group receive proper counseling about the teratogenic effects of elevated maternal plasma Phe concentration (i.e., &#x02018;maternal HPA/PKU&#x02019;) on the developing fetus [<xref ref-type="bibr" rid="pku.REF.weglage.2001.532">Weglage et al 2001</xref>] (see <xref ref-type="sec" rid="pku.Pregnancy_Management">Pregnancy Management</xref>).</p>
              </list-item>
            </list>
          </sec>
          <sec id="pku.Other_1">
            <title>Other</title>
            <p><bold>Neuropsychiatric testing</bold> may be considered to identify learning differences. Referral to appropriate developmental services is indicated to optimize developmental outcome.</p>
            <p><bold>Bone health assessment.</bold> Current literature regarding the utility of DEXA scans is controversial; however, bone health should be considered in the overall health of an affected individual [<xref ref-type="bibr" rid="pku.REF.coakley.2016.363">Coakley et al 2016</xref>].</p>
          </sec>
        </sec>
        <sec id="pku.Prevention_of_Primary_Manifestations">
          <title>Prevention of Primary Manifestations</title>
          <p>See <xref ref-type="sec" rid="pku.Treatment_of_Manifestations">Treatment of Manifestations</xref>.</p>
        </sec>
        <sec id="pku.Surveillance">
          <title>Surveillance</title>
          <p><bold>Plasma Phe and Tyr concentrations</bold> in individuals with classic PKU must be monitored regularly [<xref ref-type="bibr" rid="pku.REF.national_institutes_of_health_consensus_development_panel.2001.972">National Institutes of Health Consensus Development Panel 2001</xref>] (see <xref ref-type="sec" rid="pku.Treatment_of_Manifestations">Treatment of Manifestations</xref>).</p>
          <list list-type="bullet">
            <list-item>
              <p>In infants, frequent in-clinic visits are recommended until Phe levels are stabilized, followed by weekly blood level monitoring of Phe and tyrosine levels until age one with closer monitoring during periods of rapid growth or diet transitions. In addition, plasma amino acid levels should be regularly monitored to foster optimal growth during the first year of life.</p>
            </list-item>
            <list-item>
              <p>Between ages one and 12 years, biweekly to monthly sampling may be adequate.</p>
            </list-item>
            <list-item>
              <p>In adolescents and adults who are stable and well controlled, blood level monitoring can be monthly.</p>
            </list-item>
          </list>
          <p><bold>Nutritional assessment</bold> should include growth evaluation and assessment of micronutrient intake and needs.</p>
          <list list-type="bullet">
            <list-item>
              <p>Some clinics perform monitoring of plasma amino acids, transthyretin, complete blood count, ferritin, and 25-OH vitamin D every six months in infants and annually thereafter even if growth is appropriate and analysis of the diet shows adequate intake.</p>
            </list-item>
            <list-item>
              <p>If there is evidence for suboptimal dietary intake or over-reliance on nutritionally incomplete medical foods, evaluation of plasma amino acids (full panel), transthyretin, albumin, complete blood count, ferritin, 25-OH vitamin D, electrolytes, renal function, liver function, albumin, vitamin B<sub>12</sub>, red blood cell essential fatty acids, trace minerals (zinc, copper, selenium), vitamin A, and folic acid should be considered [<xref ref-type="bibr" rid="pku.REF.singh.2014.121">Singh et al 2014</xref>, <xref ref-type="bibr" rid="pku.REF.vockley.2014">Vockley et al 2014</xref>].</p>
            </list-item>
          </list>
          <p><bold>Assessment of developmental milestones</bold> and overall developmental progress should take place at every visit.</p>
          <p><bold>Screening for mental illness</bold> should be considered at every visit and performed at regular intervals by primary care providers.</p>
        </sec>
        <sec id="pku.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Aspartame, an artificial sweetener in widespread use, contains phenylalanine. Persons with PKU should either avoid products containing aspartame or calculate intake of Phe and adapt diet components accordingly.</p>
        </sec>
        <sec id="pku.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>It is appropriate to evaluate sibs of a proband in order to identify as early as possible those who would benefit from initiation of treatment. Note: Because phenotypic variability may be significant, previously undiagnosed and even apparently asymptomatic sibs of an affected individual may also be affected [<xref ref-type="bibr" rid="pku.REF.vockley.2014">Vockley et al 2014</xref>].</p>
          <p>Evaluations can include:</p>
          <list list-type="bullet">
            <list-item>
              <p>Measurement of blood concentration of phenylalanine and newborn screening in newborn sibs of an individual with PKU if prenatal testing was not done;</p>
            </list-item>
            <list-item>
              <p>Molecular genetic testing if the pathogenic variants in the family are known;</p>
            </list-item>
            <list-item>
              <p>Blood concentration of phenylalanine and tyrosine to clarify the disease status of older at-risk sibs if the pathogenic variants in the family are not known.</p>
            </list-item>
          </list>
          <p>See <xref ref-type="sec" rid="pku.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="pku.Pregnancy_Management">
          <title>Pregnancy Management</title>
          <sec id="pku.Women_with_PAH_Deficiency">
            <title>Women with PAH Deficiency</title>
            <p>Women with PAH deficiency who have received appropriate treatment throughout childhood and adolescence have normal physical and essentially normal intellectual and behavioral development. However, if the woman has elevated plasma Phe concentrations during pregnancy, the fetus is at high risk for malformations and intellectual disability, since phenylalanine is a potent teratogen (see <xref ref-type="sec" rid="pku.Clinical_Characteristics">Clinical Characteristics</xref>) [<xref ref-type="bibr" rid="pku.REF.rouse.2004.235">Rouse &#x00026; Azen 2004</xref>, <xref ref-type="bibr" rid="pku.REF.prick.2012.374">Prick et al 2012</xref>].</p>
            <p>The <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Genetics/Management-of-Women-With-Phenylketonuria">American College of Obstetrics and Gynecology Committee Opinion on the Management of Women with Phenylketonuria</ext-link>, the American College of Medical Genetics and Genomics guidelines on the diagnosis and management of PAH deficiency [<xref ref-type="bibr" rid="pku.REF.vockley.2014">Vockley et al 2014</xref>], and <xref ref-type="bibr" rid="pku.REF.singh.2014.121">Singh et al [2014]</xref> suggest the following management of an affected woman prior to and during pregnancy.</p>
            <p>
              <bold>Preconception</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Genetic counseling regarding the teratogenic effects of elevated maternal Phe concentration on the developing fetus and recurrence risks for PAH deficiency in the fetus</p>
              </list-item>
              <list-item>
                <p>Achievement and maintenance of the maternal Phe concentration at less than 360 &#x000b5;mol/L for three months prior to conception</p>
              </list-item>
              <list-item>
                <p>Assessment of early osteopenia risk</p>
              </list-item>
              <list-item>
                <p>Discontinuation of LNAA treatment</p>
              </list-item>
            </list>
            <p>
              <bold>During pregnancy</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Co-monitor in conjunction with practitioners from an experienced metabolic center.</p>
              </list-item>
              <list-item>
                <p>Maternal Phe concentration of 120-360 &#x000b5;mol/L during pregnancy is recommended. In unplanned pregnancies, rapid re-initiation of a Phe-restricted diet should be advised based on current knowledge of the fetal risks.</p>
              </list-item>
              <list-item>
                <p>Despite limited data, sapropterin supplementation may be appropriate in addition to dietary therapy.</p>
              </list-item>
              <list-item>
                <p>Monitor dietary intake of pregnant women with PAH deficiency to ensure nutrient adequacy with proper proportion of protein, fat, and carbohydrates.</p>
              </list-item>
              <list-item>
                <p>Evaluate for fetal anomalies by high resolution ultrasound and fetal echocardiogram.</p>
              </list-item>
            </list>
            <p>
              <bold>Post partum</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Provide coordinated care in the post-partum period</p>
              </list-item>
              <list-item>
                <p>Breast feeding may be pursued if the infant does not have PAH deficiency.</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="pku.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Although the treatment of PKU with phenylalanine-restricted diets has been hugely successful, the poor palatability of the diet results in poor compliance in adolescence and adulthood. A number of attempts to find other treatment modalities for PKU are ongoing.</p>
          <p><bold>Enzyme substitution.</bold> Under investigation is the administration of the enzyme phenylalanine ammonia lyase (PAL), a plant-derived enzyme that converts phenylalanine to trans-cinnamic acid and ammonia. The version currently under investigation is the PEGylation (conjugation with polyethylene glycol) of PAL, since it has been found to decrease the immune response to PAL [<xref ref-type="bibr" rid="pku.REF.g_mez.2005.986">G&#x000e1;mez et al 2005</xref>, <xref ref-type="bibr" rid="pku.REF.sarkissian.2005.s22">Sarkissian &#x00026; G&#x000e1;mez 2005</xref>]. Clinical trials with this protected form of injectable enzyme are currently underway. The results of the Phase I trial showed effectiveness by reducing blood Phe by 54% in the participants receiving the highest dose. The Phe level nadir was at six days and response lasted 21 days. Adverse reactions included rash, antibody accumulation to both PAL and the PEGylation component, and injection site reaction [<xref ref-type="bibr" rid="pku.REF.longo.2014.37">Longo et al 2014</xref>].</p>
          <p><bold>Cell-directed therapies.</bold> Liver repopulation with PAH-expressing cells is being investigated. Hepatocyte transplantation has been successful in animal models and in humans for other liver-based inborn errors of metabolism, such as glycogen storage disorders and urea cycle defects. Research continues to identify the best ways to allow for transferred hepatocytes to have cell growth advantage over native hepatocytes (reviewed in <xref ref-type="bibr" rid="pku.REF.strisciuglio.2014.1007">Strisciuglio &#x00026; Concolino [2014]</xref>).</p>
          <p><bold>Gene therapies.</bold> Liver-directed gene therapy does not result in a permanent correction of PAH activity in animal models. Delivery to muscle was successful in increasing conversion of Phe to Tyr in mice [Reviewed in <xref ref-type="bibr" rid="pku.REF.strisciuglio.2014.1007">Strisciuglio &#x00026; Concolino 2014</xref>].</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="pku.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="pku.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Phenylalanine hydroxylase (PAH) deficiency is inherited in an autosomal recessive manner.</p>
        </sec>
        <sec id="pku.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The parents of an affected child are obligate heterozygotes (i.e., carriers of one <italic toggle="yes">PAH</italic> pathogenic variant).</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, each sib of an affected individual has a 25% chance of being affected, a 50% chance of being an asymptomatic carrier, and a 25% chance of being unaffected and not a carrier.</p>
              <p>Significant intrafamilial variability has been observed in PAH deficiency; thus the phenotype observed in the proband may not be consistent with or predicative of the phenotype in affected sibs [<xref ref-type="bibr" rid="pku.REF.disilvestre.1991.1014">DiSilvestre et al 1991</xref>, <xref ref-type="bibr" rid="pku.REF.scriver.1999.267">Scriver &#x00026; Waters 1999</xref>, <xref ref-type="bibr" rid="pku.REF.weglage.2002.431">Weglage et al 2002</xref>, <xref ref-type="bibr" rid="pku.REF.camp.2014.87">Camp et al 2014</xref>].</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are asymptomatic and are not at risk of developing the disorder.</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Children born of one parent with PAH deficiency and one parent with two normal <italic toggle="yes">PAH</italic> alleles are obligate heterozygotes.</p>
            </list-item>
            <list-item>
              <p>If one parent is affected and the other parent is a carrier, offspring have a 50% chance of being heterozygous and a 50% chance of being affected.</p>
            </list-item>
            <list-item>
              <p>If the mother is the affected parent, maternal HPA/PKU is a critical issue (see Clinical Characteristics, <xref ref-type="sec" rid="pku.Children_Born_to_Women_with_PAH_Defi">Children Born to Women with PAH Deficiency</xref>).</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s unaffected parents is at a 50% risk of being a carrier of a <italic toggle="yes">PAH</italic> pathogenic variant.</p>
        </sec>
        <sec id="pku.Carrier_Heterozygote_Detection">
          <title>Carrier (Heterozygote) Detection</title>
          <p><bold>Molecular genetic testing</bold> for at-risk relatives requires prior identification of the <italic toggle="yes">PAH</italic> pathogenic variants in the family. ACMG guidelines recommend the use of molecular genetic testing to identify carriers in a family with a known <italic toggle="yes">PAH</italic> pathogenic variant [<xref ref-type="bibr" rid="pku.REF.vockley.2014">Vockley et al 2014</xref>]. If molecular genetic testing is not possible, biochemical analysis can be used.</p>
          <p><bold>Biochemical testing</bold> relies on plasma Phe concentration and the Phe/Tyr ratio, with or without phenylanine loading [<xref ref-type="bibr" rid="pku.REF.freehauf.1984.1180">Freehauf et al 1984</xref>, <xref ref-type="bibr" rid="pku.REF.blitzer.1986.347">Blitzer et al 1986</xref>]. Hormones associated with pregnancy have been shown to alter the Phe/Tyr ratio; thus, biochemical analysis cannot be used to determine carrier status during pregnancy, shortly after pregnancy, or with oral contraceptive use.</p>
          <p>Partners of an individual affected with or known to be a carrier of PAH deficiency may be interested in carrier testing. Analysis of <italic toggle="yes">PAH</italic> can be offered, with appropriate counseling about limits of sensitivity. Guidelines for biochemical carrier testing have not been established; and the predictive value of biochemical testing has been studied on a limited basis only.</p>
        </sec>
        <sec id="pku.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="pku.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Young women affected with PAH deficiency should receive counseling regarding the teratogenic effects of elevated maternal plasma Phe concentration (i.e., 'maternal HPA/PKU') when they reach childbearing age [<xref ref-type="bibr" rid="pku.REF.weglage.2001.532">Weglage et al 2001</xref>] (see <xref ref-type="sec" rid="pku.Pregnancy_Management">Pregnancy Management</xref>).</p>
            </list-item>
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="pku.Prenatal_Testing_and_Preimplantation">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">PAH</italic> pathogenic variants have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for PAH deficiency are possible.</p>
          <p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Prenatal diagnosis has been found by some families to be of value when decisions need to be made prenatally that will affect care of their child. Although most centers would consider decisions about prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="pku.Resources">
        <title>Resources</title>
      </sec>
      <sec id="pku.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <p><bold>Gene structure.</bold>
<italic toggle="yes">PAH</italic> contains 13 exons and spans 90 kb (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.pahdb.mcgill.ca/">PAHdb</ext-link>); the genomic sequence is known to code for a 2.6-kb mature messenger RNA. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="pku" object-id="pku.molgen.TA">Table A</related-object>, <bold>Gene</bold>.</p>
        <p><bold>Pathogenic variants.</bold> More than 900 different pathogenic variants in <italic toggle="yes">PAH</italic> have been identified to date; see <related-object source-id="gene" document-id="pku" object-id="pku.molgen.TA">Table A</related-object>, <italic toggle="yes">PAH</italic> Locus Knowledgebase and HGMD. The <italic toggle="yes">PAH</italic> Locus Knowledgebase provides information on pathogenic variants, associated phenotypes, gene structure, enzyme structure, clinical guidance, and much more [<xref ref-type="bibr" rid="pku.REF.scriver.2003.333">Scriver et al 2003</xref>]. The majority of pathogenic variants in <italic toggle="yes">PAH</italic> are missense, nonsense, frameshift, and splice variants (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.pahdb.mcgill.ca/">PAHdb</ext-link>). Large deletions account for fewer than 1% of disease alleles in most populations, but accounted for 3% of disease alleles in the Czech population [<xref ref-type="bibr" rid="pku.REF.kozak.2006.300">Kozak et al 2006</xref>].</p>
        <table-wrap id="pku.T.pah_variants_discussed_in_this_gen" orientation="portrait" position="anchor">
          <label>Table 4. </label>
          <caption>
            <p><italic toggle="yes">PAH</italic> Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
          </caption>
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias)&#x000a0;<sup>1</sup></th>
                <th id="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change</th>
                <th id="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.194T&#x0003e;C</td>
                <td headers="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ile65Thr</td>
                <td headers="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_3" rowspan="7" valign="middle" align="left" colspan="1">
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_000277.1">NM_000277.1</ext-link>
                  <break/>
                  <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/protein/NP_000268.1">NP_000268.1</ext-link>
                </td>
              </tr>
              <tr>
                <td headers="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.473G&#x0003e;A</td>
                <td headers="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Arg158Gln</td>
              </tr>
              <tr>
                <td headers="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.782G&#x0003e;A</td>
                <td headers="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg261Gln</td>
              </tr>
              <tr>
                <td headers="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.842C&#x0003e;T</td>
                <td headers="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Pro281Leu</td>
              </tr>
              <tr>
                <td headers="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">c.1066-11G&#x0003e;A<break/>(IVS10-11G&#x0003e;A)</td>
                <td headers="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
              <tr>
                <td headers="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1222C&#x0003e;T</td>
                <td headers="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Arg408Trp</td>
              </tr>
              <tr>
                <td headers="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">c.1315+1G&#x0003e;A<break/>(IVS12+1G&#x0003e;A)</td>
                <td headers="hd_h_pku.T.pah_variants_discussed_in_this_gen_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1"/>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
            </fn>
            <fn>
              <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
            </fn>
            <fn>
              <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.pahdb.mcgill.ca">www.pahdb.mcgill.ca</ext-link> and <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.biopku.org/">biopku.org</ext-link> for gene lists and databases.</p>
            </fn>
            <fn id="pku.TF.4.1">
              <label>1. </label>
              <p>Variant designation that does not conform to current naming conventions</p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
        <p><bold>Normal gene product.</bold> The normal product of <italic toggle="yes">PAH</italic> is the protein phenylalanine hydroxylase (PAH), containing 452 amino acids (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_000268.1">NP_000268.1</ext-link>). PAH enzymes can exist as tetramers and dimers in equilibrium [<xref ref-type="bibr" rid="pku.REF.hufton.1998.295">Hufton et al 1998</xref>]. The PAH enzyme hydroxylates phenylalanine to tyrosine, this reaction being the rate-limiting step in the major pathway by which phenylalanine is catabolized to CO<sub>2</sub> and water [<xref ref-type="bibr" rid="pku.REF.scriver.2001">Scriver &#x00026; Kaufman 2001</xref>].</p>
        <p><bold>Abnormal gene product.</bold> The pathogenic variants that confer the most severe phenotypes are known or predicted to completely abolish PAH activity. These &#x02018;null&#x02019; variants are of various types. Missense pathogenic variants usually permit the enzyme to retain some degree of residual activity; however, it is difficult to assess severity in vivo because the in vivo activity is not the simple equivalent of the in vitro enzymatic phenotype [<xref ref-type="bibr" rid="pku.REF.waters.1998.4">Waters et al 1998</xref>, <xref ref-type="bibr" rid="pku.REF.gjetting.2001.132">Gjetting et al 2001</xref>].</p>
      </sec>
      <sec id="pku.References">
        <title>References</title>
        <sec id="pku.Published_GuidelinesConsensus_Statem">
          <title>Published Guidelines/Consensus Statements</title>
          <ref-list id="pku.Published_GuidelinesConsensus_Statem.reflist0">
            <ref id="pku.REF1">
              <mixed-citation publication-type="web">Canadian Task Force on the Preventive Health Care. Screening for phenylketonuria. The Canadian Guide to Clinical Preventive Health Care. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://canadiantaskforce.ca/wp-content/uploads/2016/09/1994-red-brick-en.pdf">online</ext-link>. 1994. Accessed 2-8-17.</mixed-citation>
            </ref>
            <ref id="pku.REF2">
              <mixed-citation publication-type="web">Committee on Genetics. Management of woman with phenylketonuria. American College of Obstetricians and Gynecologists Committee Opinion June 2015. Number 636. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.acog.org/Resources-And-Publications/Committee-Opinions/Committee-on-Genetics/Management-of-Women-With-Phenylketonuria">online</ext-link>. 2015. Accessed 2-8-17.</mixed-citation>
            </ref>
            <ref id="pku.REF.singh.2014.121">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohr</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frazier</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cunningham</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mofidi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogata</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Splett</surname>
                    <given-names>PL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moseley</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huntington</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acosta</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vockley</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Calcar</surname>
                    <given-names>SC</given-names>
                  </name>
                </person-group>
                <article-title>Recommendations for the nutrition management of phenylalanine hydroxylase deficiency.</article-title>
                <source>Genet Med</source>
                <year>2014</year>
                <volume>16</volume>
                <fpage>121</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">24385075</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF4">
              <mixed-citation publication-type="web">US Preventive Services Task Force. Screening for phenylketonuria (PKU). Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.uspreventiveservicestaskforce.org/uspstf/uspsspku.htm">online</ext-link>. 2008. Accessed 2-8-17</mixed-citation>
            </ref>
            <ref id="pku.REF.vockley.2014">
              <mixed-citation publication-type="web">Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, Mitchell J, Smith WE, Thompson BH, Berry SA; American College of Medical Genetics and Genomics Therapeutics Committee. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Available <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.nature.com/gim/journal/v16/n2/full/gim2013157a.html">online</ext-link>. 2014. Accessed 2-8-17.</mixed-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="pku.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="pku.Literature_Cited.reflist0">
            <ref id="pku.REF.anderson.2010.s3">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leuzzi</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <article-title>White matter pathology in phenylketonuria.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2010</year>
                <volume>99</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S3</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">20123467</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.antshel.2010.s52">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Antshel</surname>
                    <given-names>KM</given-names>
                  </name>
                </person-group>
                <article-title>ADHD, learning, and academic performance in phenylketonuria.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2010</year>
                <volume>99</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S52</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">20123471</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.aoki.1988.429">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Aoki</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wada</surname>
                    <given-names>Y</given-names>
                  </name>
                </person-group>
                <article-title>Outcome of the patients detected by newborn screening in Japan.</article-title>
                <source>Acta Paediatr Jpn.</source>
                <year>1988</year>
                <volume>30</volume>
                <fpage>429</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">3150232</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.bernegger.2002.304">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bernegger</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1,919 patients observed from 1988 to 2002.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2002</year>
                <volume>77</volume>
                <fpage>304</fpage>
                <lpage>13</lpage>
                <pub-id pub-id-type="pmid">12468276</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.bilder.2013.155">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bilder</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burton</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coon</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leviton</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ashworth</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lundy</surname>
                    <given-names>BD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vespa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bakian</surname>
                    <given-names>AV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longo</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Psychiatric symptoms in adults with phenylketonuria.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2013</year>
                <volume>108</volume>
                <fpage>155</fpage>
                <lpage>60</lpage>
                <pub-id pub-id-type="pmid">23339767</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.blau.2010.109">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000e9;langer-Quintana</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Demirkol</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feillet</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giovannini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trefz</surname>
                    <given-names>FK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Spronsen</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>European PKU centers. Management of phenylketonuria in Europe: survey results from 19 countries.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2010</year>
                <volume>99</volume>
                <fpage>109</fpage>
                <lpage>15</lpage>
                <pub-id pub-id-type="pmid">19800826</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.blau.2001">
              <mixed-citation publication-type="book">Blau N, Th&#x000f6;ny B, Cotton RGH, Hyland K. Disorders of tetrahydrobiopterin and related biogenic amines. In: Scriver CR, Kaufman S, Eisensmith E, Woo SLC, Vogelstein B, Childs B, eds. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Disease</italic>. 8 ed. New York: McGraw Hill; 2001:1725-76.</mixed-citation>
            </ref>
            <ref id="pku.REF.blitzer.1986.347">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Blitzer</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bailey-Wilson</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shapira</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Discrimination of heterozygotes for phenylketonuria, persistent hyperphenylalaninemia and controls by phenylalanine loading.</article-title>
                <source>Clin Chim Acta.</source>
                <year>1986</year>
                <volume>161</volume>
                <fpage>347</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">3802540</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.brumm.2010.s59">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brumm</surname>
                    <given-names>VL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bilder</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waisbren</surname>
                    <given-names>SE</given-names>
                  </name>
                </person-group>
                <article-title>Psychiatric symptoms and disorders in phenylketonuria.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2010</year>
                <volume>99</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S59</fpage>
                <lpage>63</lpage>
                <pub-id pub-id-type="pmid">20123472</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.brumm.2010.s18">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brumm</surname>
                    <given-names>VL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grant</surname>
                    <given-names>ML</given-names>
                  </name>
                </person-group>
                <article-title>The role of intelligence in phenylketonuria: a review of research and management.</article-title>
                <source>Mol Genet Metab</source>
                <year>2010</year>
                <volume>99</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S18</fpage>
                <lpage>21</lpage>
                <pub-id pub-id-type="pmid">20123465</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.burgard.1999.46">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Burgard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bremer</surname>
                    <given-names>HJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>B&#x000fc;hrdel</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clemens</surname>
                    <given-names>PC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000f6;nch</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Przyrembel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trefz</surname>
                    <given-names>FK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ullrich</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997.</article-title>
                <source>Eur J Pediatr.</source>
                <year>1999</year>
                <volume>158</volume>
                <fpage>46</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">9950308</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.burton.2013.8">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Burton</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leviton</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vespa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coon</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lundy</surname>
                    <given-names>BD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Angelino</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hamosh</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bilder</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>A diversified approach for PKU treatment: Routine screening yields high incidence of psychiatric distress in phenylketonuria clinics.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2013</year>
                <volume>108</volume>
                <fpage>8</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">23266195</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.camp.2014.87">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Camp</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parisi</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Acosta</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry</surname>
                    <given-names>GT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bilder</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bodamer</surname>
                    <given-names>OA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brosco</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burlina</surname>
                    <given-names>AB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burton</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chang</surname>
                    <given-names>CS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coates</surname>
                    <given-names>PM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cunningham</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dobrowolski</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferguson</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Franklin</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frazier</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grange</surname>
                    <given-names>DK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greene</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groft</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harding</surname>
                    <given-names>CO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Howell</surname>
                    <given-names>RR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huntington</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyatt-Knorr</surname>
                    <given-names>HD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jevaji</surname>
                    <given-names>IP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>HL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lichter-Konecki</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindegren</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lloyd-Puryear</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matalon</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McPheeters</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mofidi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moseley</surname>
                    <given-names>KD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mueller</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mulberg</surname>
                    <given-names>AE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nerurkar</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ogata</surname>
                    <given-names>BN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pariser</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prasad</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pridjian</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rasmussen</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reddy</surname>
                    <given-names>UM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rohr</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>RH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sirrs</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stremer</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tagle</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Urv</surname>
                    <given-names>TK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Utz</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Spronsen</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vockley</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waisbren</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weglicki</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>DA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whitley</surname>
                    <given-names>CB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilfond</surname>
                    <given-names>BS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yannicelli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Young</surname>
                    <given-names>JM.</given-names>
                  </name>
                </person-group>
                <article-title>Phenylketonuria Scientific Review Conference: state of the science and future research needs.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2014</year>
                <volume>112</volume>
                <fpage>87</fpage>
                <lpage>122</lpage>
                <pub-id pub-id-type="pmid">24667081</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.channon.2007.213">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Channon</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zlotowitz</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mockler</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <article-title>Effects of dietary management of phenylketonuria on long-term cognitive outcome.</article-title>
                <source>Arch Dis Child.</source>
                <year>2007</year>
                <volume>92</volume>
                <fpage>213</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17068073</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.coakley.2016.363">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Coakley</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Douglas</surname>
                    <given-names>TD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodman</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramakrishnan</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dobrowolski</surname>
                    <given-names>SF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>RH</given-names>
                  </name>
                </person-group>
                <article-title>Modeling correlates of low bone mineral density in patients with phenylalanine hydroxylase deficiency.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2016</year>
                <volume>39</volume>
                <fpage>363</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">26883219</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.demirdas.2015.17">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Demirdas</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coakley</surname>
                    <given-names>KE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bisshop</surname>
                    <given-names>PH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bosch</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Singh</surname>
                    <given-names>RH</given-names>
                  </name>
                </person-group>
                <article-title>Bone health in phenylketonuria: a systematic review and meta-analysis.</article-title>
                <source>Orphanet J Rare Dis.</source>
                <year>2015</year>
                <volume>10</volume>
                <fpage>17</fpage>
                <pub-id pub-id-type="pmid">25758373</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.dilella.1986.743">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>DiLella</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kwok</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ledley</surname>
                    <given-names>FD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marvit</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Woo</surname>
                    <given-names>SL</given-names>
                  </name>
                </person-group>
                <article-title>Molecular structure and polymorphic map of the human phenylalanine hydroxylase gene.</article-title>
                <source>Biochemistry.</source>
                <year>1986</year>
                <volume>25</volume>
                <fpage>743</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">3008810</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.disilvestre.1991.1014">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>DiSilvestre</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Groffen</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Different clinical manifestations of hyperphenylalaninemia in three siblings with identical phenylalanine hydroxylase genes.</article-title>
                <source>Am J Hum Genet.</source>
                <year>1991</year>
                <volume>48</volume>
                <fpage>1014</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">2018035</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.fonnesbeck.2013.757">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fonnesbeck</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McPheeters</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krishnaswami</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lindegren</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reimschisel</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>Estimating the probability of IQ impairment from blood phenylalanine for phenylketonuria patients: a hierarchical meta-analysis.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2013</year>
                <volume>36</volume>
                <fpage>757</fpage>
                <lpage>66</lpage>
                <pub-id pub-id-type="pmid">23197105</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.freehauf.1984.1180">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Freehauf</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lezotte</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goodman</surname>
                    <given-names>SI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McCabe</surname>
                    <given-names>ER</given-names>
                  </name>
                </person-group>
                <article-title>Carrier screening for phenylketonuria: comparison of two discriminant analysis procedures.</article-title>
                <source>Am J Hum Genet.</source>
                <year>1984</year>
                <volume>36</volume>
                <fpage>1180</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">6517048</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.gable.2003.379">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gable</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Williams</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stephenson</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Okano</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ring</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hurtubise</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tyfield</surname>
                    <given-names>L</given-names>
                  </name>
                </person-group>
                <article-title>Comparative multiplex dosage analysis detects whole exon deletions at the phenylalanine hydroxylase locus.</article-title>
                <source>Hum Mutat.</source>
                <year>2003</year>
                <volume>21</volume>
                <fpage>379</fpage>
                <lpage>86</lpage>
                <pub-id pub-id-type="pmid">12655547</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.g_mez.2005.986">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>G&#x000e1;mez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarkissian</surname>
                    <given-names>CN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kim</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Straub</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Patch</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Striepeke</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fitzpatrick</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lemontt</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Neill</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scriver</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevens</surname>
                    <given-names>RC</given-names>
                  </name>
                </person-group>
                <article-title>Development of pegylated forms of recombinant Rhodosporidium toruloides phenylalanine ammonia-lyase for the treatment of classical phenylketonuria.</article-title>
                <source>Mol Ther.</source>
                <year>2005</year>
                <volume>11</volume>
                <fpage>986</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15922970</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.gjetting.2001.132">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gjetting</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petersen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guldberg</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000fc;ttler</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>In vitro expression of 34 naturally occurring mutant variants of phenylalanine hydroxylase: correlation with metabolic phenotypes and susceptibility toward protein aggregation.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2001</year>
                <volume>72</volume>
                <fpage>132</fpage>
                <lpage>43</lpage>
                <pub-id pub-id-type="pmid">11161839</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.guldberg.1998.71">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Guldberg</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rey</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zschocke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Romano</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fran&#x000e7;ois</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Michiels</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ullrich</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burgard</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meli</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Riva</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dianzani</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ponzone</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rey</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000fc;ttler</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <article-title>A European multicenter study of phenylalanine hydroxylase deficiency: classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype.</article-title>
                <source>Am J Hum Genet.</source>
                <year>1998</year>
                <volume>63</volume>
                <fpage>71</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">9634518</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.g_ttler.2006">
              <mixed-citation publication-type="book">G&#x000fc;ttler F, Guldberg P. Genotype/phenotype correlations in phenylalanine hydroxylase deficiency. In: Blau N, ed. <italic toggle="yes">PKU and BH4 &#x02013; Advances in Phenylketonuria and Tetrahydrobiopterin.</italic> Heilbronn, Germany: SPS Verlagsgesellschaft; 2006:211-320.</mixed-citation>
            </ref>
            <ref id="pku.REF.hanley.2011.23">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hanley</surname>
                    <given-names>WB</given-names>
                  </name>
                </person-group>
                <article-title>Non-PKU mild hyperphenylalaninemia (MHP)--the dilemma.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2011</year>
                <volume>104</volume>
                <fpage>23</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">21632269</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.ho.2014.49">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ho</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christodoulou</surname>
                    <given-names>J.</given-names>
                  </name>
                </person-group>
                <article-title>Phenylketonuria: translating research into novel therapies.</article-title>
                <source>Transl Pediatr.</source>
                <year>2014</year>
                <volume>3</volume>
                <fpage>49</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">26835324</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.hufton.1998.295">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hufton</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jennings</surname>
                    <given-names>IG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cotton</surname>
                    <given-names>RG</given-names>
                  </name>
                </person-group>
                <article-title>Structure/function analysis of the domains required for the multimerisation of phenylalanine hydroxylase.</article-title>
                <source>Biochim Biophys Acta.</source>
                <year>1998</year>
                <volume>1382</volume>
                <fpage>295</fpage>
                <lpage>304</lpage>
                <pub-id pub-id-type="pmid">9540801</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.huijbregts.2002.419">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Huijbregts</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Sonneville</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Licht</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Spronsen</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sergeant</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <article-title>Short-term dietary interventions in children and adolescents with treated phenylketonuria: effects on neuropsychological outcome of a well-controlled population.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2002</year>
                <volume>25</volume>
                <fpage>419</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">12555935</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.jahja.2016.355">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jahja</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Spronsen</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Sonneville</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Meere</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bosch</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hollak</surname>
                    <given-names>CE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rubio-Gozalbo</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brouwers</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hofstede</surname>
                    <given-names>FC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Vries</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janssen</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van der Ploeg</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Langendonk</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huijbregts</surname>
                    <given-names>SC</given-names>
                  </name>
                </person-group>
                <article-title>Social-cognitive functioning and social skills in patients with early treated phenylketonuria: a PKU-COBESO study</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2016</year>
                <volume>39</volume>
                <fpage>355</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">26914933</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.kayaalp.1997.1309">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kayaalp</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Treacy</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Byck</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nowacki</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scriver</surname>
                    <given-names>CR</given-names>
                  </name>
                </person-group>
                <article-title>Human phenylalanine hydroxylase mutations and hyperphenylalaninemia phenotypes: a metanalysis of genotype-phenotype correlations.</article-title>
                <source>Am J Hum Genet.</source>
                <year>1997</year>
                <volume>61</volume>
                <fpage>1309</fpage>
                <lpage>17</lpage>
                <pub-id pub-id-type="pmid">9399896</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.koch.2002.333">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burton</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoganson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peterson</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rhead</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rouse</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolff</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stern</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000fc;ttler</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nelson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de la Cruz</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coldwell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erbe</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Geraghty</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shear</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thomas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azen</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Phenylketonuria in adulthood: a collaborative study.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2002</year>
                <volume>25</volume>
                <fpage>333</fpage>
                <lpage>46</lpage>
                <pub-id pub-id-type="pmid">12408183</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.kozak.2006.300">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kozak</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hrabincova</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kintr</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horky</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zapletalova</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blahakova</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mejstrik</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prochazkova</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>Identification and characterization of large deletions in the phenylalanine hydroxylase (PAH) gene by MLPA: evidence for both homologous and non-homologous mechanisms of rearrangement.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2006</year>
                <volume>89</volume>
                <fpage>300</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">16931086</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.leuders.2014.101">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Leuders</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolfgart</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ott</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>du Moulin</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Teeffelen-Heithoff</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vogelpohl</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Och</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marquardt</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weglage</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feldmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rutsch</surname>
                    <given-names>F.</given-names>
                  </name>
                </person-group>
                <article-title>Influence of PAH Genotype on Sapropterin Response in PKU: Results of a Single-Center Cohort Study.</article-title>
                <source>JIMD Rep.</source>
                <year>2014</year>
                <volume>13</volume>
                <fpage>101</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">24190797</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.longo.2014.37">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Longo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harding</surname>
                    <given-names>CO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burton</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grange</surname>
                    <given-names>DK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vockley</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wasserstein</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rice</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dorenbaum</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Neuenburg</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Musson</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gu</surname>
                    <given-names>Z</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sile</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Single-dose, subcutaneous recombinant phenylalanine ammonia lyase conjugated with polyethylene glycol in adult patients with phenylketonuria: an open-label, multicentre, phase 1 dose-escalation trial.</article-title>
                <source>Lancet.</source>
                <year>2014</year>
                <volume>384</volume>
                <fpage>37</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">24743000</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.modanmoses.2007.202">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Modan-Moses</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vered</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anikster</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abraham</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Segev</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Efrati</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <article-title>Peak bone mass in patients with phenylketonuria.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2007</year>
                <volume>30</volume>
                <fpage>202</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">17347917</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.moyle.2007.91">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Moyle</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fox</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arthur</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bynevelt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burnett</surname>
                    <given-names>JR</given-names>
                  </name>
                </person-group>
                <article-title>Meta-analysis of neuropsychological symptoms of adolescents and adults with PKU.</article-title>
                <source>Neuropsychol Rev.</source>
                <year>2007</year>
                <volume>17</volume>
                <fpage>91</fpage>
                <lpage>101</lpage>
                <pub-id pub-id-type="pmid">17410469</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.national_institutes_of_health_consensus_development_panel.2001.972">
              <element-citation publication-type="journal">
                <person-group>
                  <collab>National Institutes of Health Consensus Development Panel</collab>
                </person-group>
                <article-title>National Institutes of Health Consensus Development Conference Statement: phenylketonuria: screening and management, October 16-18, 2000.</article-title>
                <source>Pediatrics.</source>
                <year>2001</year>
                <volume>108</volume>
                <fpage>972</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">11581453</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.ozalp.2001.97">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ozalp</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coskun</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tokatli</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalkanoglu</surname>
                    <given-names>HS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dursun</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tokol</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koksal</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozguc</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kose</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <article-title>Newborn PKU screening in Turkey: at present and organization for future.</article-title>
                <source>Turk J Pediatr.</source>
                <year>2001</year>
                <volume>43</volume>
                <fpage>97</fpage>
                <lpage>101</lpage>
                <pub-id pub-id-type="pmid">11432505</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.p_rezdue_as.2002.899">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>P&#x000e9;rez-Due&#x000f1;as</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cambra</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilaseca</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lambruschini</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campistol</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Camacho</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <article-title>New approach to osteopenia in phenylketonuric patients.</article-title>
                <source>Acta Paediatr.</source>
                <year>2002</year>
                <volume>91</volume>
                <fpage>899</fpage>
                <lpage>904</lpage>
                <pub-id pub-id-type="pmid">12222712</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.p_rezdue_as.2004.1083">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>P&#x000e9;rez-Due&#x000f1;as</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vilaseca</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mas</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lambruschini</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Artuch</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000f3;mez</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pineda</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guti&#x000e9;rrez</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mila</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campistol</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Tetrahydrobiopterin responsiveness in patients with phenylketonuria.</article-title>
                <source>Clin Biochem.</source>
                <year>2004</year>
                <volume>37</volume>
                <fpage>1083</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">15589814</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.pietz.1998.824">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pietz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dunckelmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rupp</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rating</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meinck</surname>
                    <given-names>HM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmidt</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bremer</surname>
                    <given-names>HJ</given-names>
                  </name>
                </person-group>
                <article-title>Neurological outcome in adult patients with early-treated phenylketonuria.</article-title>
                <source>Eur J Pediatr.</source>
                <year>1998</year>
                <volume>157</volume>
                <fpage>824</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">9809823</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.ponzone.2006">
              <mixed-citation publication-type="book">Ponzone A, Ferraris S, Baglieri S, Spada M. Treatment of tetrahydrobiopterin deficiencies. In: Blau N, ed. <italic toggle="yes">PKU and BH4 Advances in Phenylketonuria and Tetrahydrobiopterin.</italic> Heilbronn, Germany: SPS Verlagsgesellschaft; 2006:612-37.</mixed-citation>
            </ref>
            <ref id="pku.REF.prick.2012.374">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Prick</surname>
                    <given-names>BW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hop</surname>
                    <given-names>WC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duvekot</surname>
                    <given-names>JJ</given-names>
                  </name>
                </person-group>
                <article-title>Maternal phenylketonuria and hyperphenylalaninemia in pregnancy: pregnancy complications and neonatal sequelae in untreated and treated pregnancies.</article-title>
                <source>Am J Clin Nutr.</source>
                <year>2012</year>
                <volume>95</volume>
                <fpage>374</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">22205310</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.robinson.2000.545">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>White</surname>
                    <given-names>FJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cleary</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wraith</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lam</surname>
                    <given-names>WK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Walter</surname>
                    <given-names>JH</given-names>
                  </name>
                </person-group>
                <article-title>Increased risk of vitamin B12 deficiency in patients with phenylketonuria on an unrestricted or relaxed diet.</article-title>
                <source>J Pediatr.</source>
                <year>2000</year>
                <volume>136</volume>
                <fpage>545</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">10753257</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.rouse.2004.235">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rouse</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Azen</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Effect of high maternal blood phenylalanine on offspring congenital anomalies and developmental outcome at ages 4 and 6 years: the importance of strict dietary control preconception and throughout pregnancy.</article-title>
                <source>J Pediatr.</source>
                <year>2004</year>
                <volume>144</volume>
                <fpage>235</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14760268</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.santos.2010.1">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Santos</surname>
                    <given-names>LL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fonseca</surname>
                    <given-names>CG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Starling</surname>
                    <given-names>AL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Janu&#x000e1;rio</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aguiar</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peixoto</surname>
                    <given-names>MG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carvalho</surname>
                    <given-names>MR</given-names>
                  </name>
                </person-group>
                <article-title>Variations in genotype-phenotype correlations in phenylketonuria patients.</article-title>
                <source>Genet Mol Res.</source>
                <year>2010</year>
                <volume>9</volume>
                <fpage>1</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">20082265</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.sarkissian.2005.s22">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sarkissian</surname>
                    <given-names>CN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000e1;mez</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <article-title>Phenylalanine ammonia lyase, enzyme substitution therapy for phenylketonuria, where are we now?</article-title>
                <source>Mol Genet Metab.</source>
                <year>2005</year>
                <volume>86</volume>
                <supplement>Suppl 1</supplement>
                <fpage>S22</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16165390</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.scriver.2003.333">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Scriver</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hurtubise</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konecki</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Phommarinh</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prevost</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Erlandsen</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stevens</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ryan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarkissian</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>PAHdb 2003: what a locus-specific knowledgebase can do.</article-title>
                <source>Hum Mutat.</source>
                <year>2003</year>
                <volume>21</volume>
                <fpage>333</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">12655543</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.scriver.2001">
              <mixed-citation publication-type="book">Scriver CR, Kaufman S. Hyperphenylalaninemia: phenylalanine hydroxylase deficiency. In: Scriver CR, Beaudet AL, Sly SW, Valle D, eds; Childs B, Kinzler KW, Vogelstein B, assoc eds. <italic toggle="yes">The Metabolic and Molecular Bases of Inherited Disease.</italic> 8 ed. New York, NY: McGraw-Hill; 2001:1667-724.</mixed-citation>
            </ref>
            <ref id="pku.REF.scriver.1999.267">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Scriver</surname>
                    <given-names>CR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>PJ</given-names>
                  </name>
                </person-group>
                <article-title>Monogenic traits are not simple: lessons from phenylketonuria.</article-title>
                <source>Trends Genet.</source>
                <year>1999</year>
                <volume>15</volume>
                <fpage>267</fpage>
                <lpage>72</lpage>
                <pub-id pub-id-type="pmid">10390625</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.strisciuglio.2014.1007">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Strisciuglio</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Concolino</surname>
                    <given-names>D</given-names>
                  </name>
                </person-group>
                <article-title>New strategies for the treatment of phenylketonuria (PKU).</article-title>
                <source>Metabolites</source>
                <year>2014</year>
                <volume>4</volume>
                <fpage>1007</fpage>
                <lpage>17</lpage>
                <pub-id pub-id-type="pmid">25375236</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.van_spronsen.2011.651">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>van Spronsen</surname>
                    <given-names>FJ</given-names>
                  </name>
                </person-group>
                <article-title>Mild hyperphenylalaninemia: to treat or not to treat.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2011</year>
                <volume>34</volume>
                <fpage>651</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">21347590</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.vockley.2014.188">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Vockley</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Andersson</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antshel</surname>
                    <given-names>KM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braverman</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burton</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frazier</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mitchell</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>WE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thompson</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berry</surname>
                    <given-names>SA</given-names>
                  </name>
                </person-group>
                <article-title>Phenylalanine hydroxylase deficiency: diagnosis and management guideline.</article-title>
                <source>Genet Med.</source>
                <year>2014</year>
                <volume>16</volume>
                <fpage>188</fpage>
                <lpage>200</lpage>
                <pub-id pub-id-type="pmid">24385074</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.waisbren.2007.63">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Waisbren</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Noel</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fahrbach</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cella</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Frame</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dorenbaum</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Levy</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Phenylalanine blood levels and clinical outcomes in phenylketonuria: a systematic literature review and meta-analysis.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2007</year>
                <volume>92</volume>
                <fpage>63</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">17591452</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.waters.1998.4">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parniak</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nowacki</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scriver</surname>
                    <given-names>CR</given-names>
                  </name>
                </person-group>
                <article-title>In vitro expression analysis of mutations in phenylalanine hydroxylase: linking genotype to phenotype and structure to function.</article-title>
                <source>Hum Mutat.</source>
                <year>1998</year>
                <volume>11</volume>
                <fpage>4</fpage>
                <lpage>17</lpage>
                <pub-id pub-id-type="pmid">9450897</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.weglage.2000.83">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weglage</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oberwittler</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marquardt</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schellscheidt</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>von Teeffelen-Heithoff</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gerding</surname>
                    <given-names>H.</given-names>
                  </name>
                </person-group>
                <article-title>Neurological deterioration in adult phenylketonuria.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2000</year>
                <volume>23</volume>
                <fpage>83</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">10682311</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.weglage.2001.532">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weglage</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pietsch</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feldmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zschocke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Muntau-Heger</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Denecke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Guldberg</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000fc;ttler</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000f6;ller</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wendel</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ullrich</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harms</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <article-title>Normal clinical outcome in untreated subjects with mild hyperphenylalaninemia.</article-title>
                <source>Pediatr Res.</source>
                <year>2001</year>
                <volume>49</volume>
                <fpage>532</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">11264437</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.weglage.2002.431">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Weglage</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiedermann</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Denecke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Feldmann</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>HG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ullrich</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000f6;ller</surname>
                    <given-names>HE</given-names>
                  </name>
                </person-group>
                <article-title>Individual blood-brain barrier phenylalanine transport in siblings with classical phenylketonuria.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2002</year>
                <volume>25</volume>
                <fpage>431</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12555936</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.zeman.1999.1348">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zeman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Step&#x000e1;n</surname>
                    <given-names>J</given-names>
                  </name>
                </person-group>
                <article-title>Bone mineral density in patients with phenylketonuria.</article-title>
                <source>Acta Paediatr.</source>
                <year>1999</year>
                <volume>88</volume>
                <fpage>1348</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">10626520</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.zschocke.2012">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zschocke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haverkamp</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>M&#x000f8;ller</surname>
                    <given-names>LB</given-names>
                  </name>
                </person-group>
                <article-title>Clinical utility gene card for: Phenylketonuria.</article-title>
                <source>Eur J Hum Genet.</source>
                <year>2012</year>
                <volume>20</volume>
                <issue>2</issue>
                <pub-id pub-id-type="pmid">21915151</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.zschocke.2000.s154">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zschocke</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hoffmann</surname>
                    <given-names>GF</given-names>
                  </name>
                </person-group>
                <article-title>PAH gene mutation analysis in clinical practice--comments on mutation analysis anticipates dietary requirements in phenylketonuria.</article-title>
                <source>Eur J Pediatr.</source>
                <year>2000</year>
                <volume>159</volume>
                <supplement>Suppl 2</supplement>
                <fpage>S154</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">11043163</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.zurfl_h.2006.725">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Zurfl&#x000fc;h</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fiori</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fiege</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ozen</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Demirkol</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>G&#x000e4;rtner</surname>
                    <given-names>KH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Th&#x000f6;ny</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Giovannini</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Pharmacokinetics of orally administered tetrahydrobiopterin in patients with phenylalanine hydroxylase deficiency.</article-title>
                <source>J Inherit Metab Dis.</source>
                <year>2006</year>
                <volume>29</volume>
                <fpage>725</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">17091341</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="pku.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="pku.Suggested_Reading.reflist0">
            <ref id="pku.REF.berry.2013.591">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Berry</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brown</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grant</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greene</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jurecki</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moseley</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suter</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Calcar</surname>
                    <given-names>SC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wiles</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cederbaum</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <article-title>Newborn screening 50 years later: access issues faced by adults with PKU.</article-title>
                <source>Genet Med.</source>
                <year>2013</year>
                <volume>15</volume>
                <fpage>591</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23470838</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.brosco.2013.987">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Brosco</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paul</surname>
                    <given-names>DB</given-names>
                  </name>
                </person-group>
                <article-title>The political history of PKU: reflections on 50 years of newborn screening.</article-title>
                <source>Pediatrics.</source>
                <year>2013</year>
                <volume>132</volume>
                <fpage>987</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">24276841</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.groselj.2014.8">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Groselj</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tansek</surname>
                    <given-names>MZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Battelino</surname>
                    <given-names>T</given-names>
                  </name>
                </person-group>
                <article-title>Fifty years of phenylketonuria newborn screening - A great success for many, but what about the rest?</article-title>
                <source>Mol Genet Metab.</source>
                <year>2014</year>
                <volume>113</volume>
                <fpage>8</fpage>
                <lpage>10</lpage>
                <pub-id pub-id-type="pmid">25174964</pub-id>
              </element-citation>
            </ref>
            <ref id="pku.REF.matern.2014">
              <mixed-citation publication-type="book">Matern D, Greene CL. Newborn screening for inborn errors of metabolism. In: Blau N, Duran M, Gibson KM, Dionisi-Visi C, eds. <italic toggle="yes">Physician&#x02019;s guide to the Diagnosis, Treatment, and Follow-up of Metabolic Diseases</italic>. Springer; 2014:719-35.</mixed-citation>
            </ref>
            <ref id="pku.REF.pollitt.2012.927">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pollitt</surname>
                    <given-names>RJ</given-names>
                  </name>
                </person-group>
                <article-title>Commentary: What degree of hyperphenylalaninemia requires treatment?</article-title>
                <source>J Inherit Metab Dis</source>
                <year>2012</year>
                <volume>35</volume>
                <fpage>927</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">22718276</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="pku.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="pku.Author_History">
          <title>Author History</title>
          <p>Carol L Greene, MD, FAAP, FACMG (2016-present) John J Mitchell, MD; McGill University, Montreal (2005-2016) Debra S Regier, MD, PhD, FAAP, FACMG (2016-present)Shannon Ryan, MSc; Montreal Children's Hospital (2000-2005)Charles R Scriver, MD; Montreal Children&#x02019;s Hospital (2000-2013)</p>
        </sec>
        <sec id="pku.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>5 January 2017 (sr) Revision: corrections suggested by expert reader</p>
            </list-item>
            <list-item>
              <p>20 October 2016 (ma) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>31 January 2013 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>4 May 2010 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>29 March 2007 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>19 July 2005 (jm) Revision: duplication/deletion testing clinically available</p>
            </list-item>
            <list-item>
              <p>8 July 2004 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>13 August 2002 (me) Comprehensive update posted to live Web site</p>
            </list-item>
            <list-item>
              <p>10 January 2000 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>16 July 1999 (sr) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
